英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Biotech Company - Juvenescence
    Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medicines Our approach centres around developing medicines that target core pathways of aging to not only treat but prevent age-related diseases, ensuring that longevity comes with enhanced quality of life By focusing on early disease intervention and prevention, we are
  • Our Pipeline - Juvenescence
    Our core medicines (JuvTherapeutics) are comprised of therapeutics developed by the Juvenescence team, targeting fundamental aging mechanisms with a near-term age-related first indication identified for clinical development
  • News - Juvenescence
    M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases
  • Our Team - Juvenescence
    Leaders in Biopharmaceutical Innovation Our leadership team is a coalition of disruptors with over 150 years of combined R D experience and a history of delivering two of the 10 largest biopharma deals of the last century They are committed to advancing the future of medicine, creating approved medicines, and consistently delivering value to our shareholders
  • February 26, 2026 - Juvenescence
    Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517) demonstrates good safety and […]
  • Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor
    Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for in patients with metabolic and fibrotic disease Carmel Nanthakumar, PhD, joins as VP, Translational Biology, following recent appointments of
  • Juvenescence acquires AI drug discovery company Ro5
    In addition, Juvenescence has investments in a number of cutting-edge companies and platform technologies focused on AI and regenerative medicine About Ro5 In the race to improve global health, Ro5 accelerates drug discovery and development with a powerful fusion of data mining, computational chemistry, and cutting-edge AI
  • Science - Juvenescence
    SCIENTIFIC APPROACH What Causes Aging? We base our work on breakthrough scientific discoveries that target the underlying biological causes of aging 85% of older adults have at least one chronic health condition, and 60% have at least two We believe that when aging slows, the onset of chronic disease will slow with it Aging Accelerates Chronic
  • Juvenescence closes $76m first tranche of Series B-1 financing led by . . .
    Ramsey, Isle of Man, 21 May 2025: Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce that it has secured a total of $76m in the first-close of a Series B-1 round, led by cornerstone investor M42, with follow-on investments from existing investors
  • Jim Mellon - Juvenescence
    Jim MellonDeputy Chairman Co-Founder Jim Mellon, a co-founder and Deputy Chairman of Juvenescence, was inspired by the possibilities and advances being made in the area of longevity He travelled across the world, speaking to leading scientists and researchers, and from those conversations, he wrote the book, Juvenescence That book and his partnership with Greg Bailey





中文字典-英文字典  2005-2009